Results from a prospective study of individuals' symptoms and patient activation after hepatitis C treatment.
antiviral agents
health status
hepatitis C
quality of life
symptom burden
Journal
Research in nursing & health
ISSN: 1098-240X
Titre abrégé: Res Nurs Health
Pays: United States
ID NLM: 7806136
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
22
05
2020
revised:
20
10
2020
accepted:
22
10
2020
pubmed:
11
11
2020
medline:
2
3
2021
entrez:
10
11
2020
Statut:
ppublish
Résumé
The treatment of the hepatitis C virus has been revolutionized by the discovery of direct-acting antiviral medications, which offer more effective treatment with fewer potential side effects. Few studies have examined changes in patient-reported outcomes in individuals undergoing treatment for the hepatitis C virus in the immediate time period after the first treatment (within 1 month). This study is one of the first to use quantitative and qualitative methods to investigate changes in quality of life, patient activation, and symptom burden in adults undergoing treatment for hepatitis C virus with direct-acting antiviral medications. Seventy-three patients were followed in a prospective, longitudinal mixed-methods design. Changes pre and posttreatment in quality of life, patient activation, and symptom burden were very small in magnitude when looking across the entire sample. However, patients with lower self-reported health at baseline reported improved physical and psychological functioning 1-month posttreatment. Patients with higher self-reported health at baseline reported decreased general health posttreatment, although these effects were small. Qualitative results suggested that most patients found symptoms to be manageable despite experiencing both psychological and physical symptoms during treatment. We also found that 25% of patients had low levels of patient activation and may lack the basic knowledge and confidence to be an active participant in their health care. These findings suggest that patients may benefit from tailored information based on current health status about what to expect during and immediately after beginning direct-acting antiviral medication treatment.
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
662-672Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Aaronson, N. K., Acquadro, C., Alonso, J., Apolone, G., Bucquet, D., Bullinger, M., Bungay, K., Fukuhara, S., Gandek, B., Keller, S., Razavi, D., Sanson-Fisher, R., Sullivan, M., Wood-Dauphinee, S., Wagner, A., & Ware, J. E. (1992). International quality of life assessment (IQOLA) project. Quality of Life Research, 1(5), 349-351. https://doi.org/10.1007/BF00434949
Asselah, T., Boyer, N., Saadoun, D., Martinot-Peignoux, M., & Marcellin, P. (2016). Direct-acting antivirals for the treatment of hepatitis C virus infection: Optimizing current IFN-free treatment and future perspectives. Liver International, 36, 47-57. https://doi.org/10.1111/liv.13027
Centers for Disease Control and Prevention. (2019). Surveillance for Viral Hepatitis-United States, 2017. https://www.cdc.gov/hepatitis/statistics/2017surveillance/index.htm
Centers for Disease Control-United States. (2020). Hepatitis C. https://www.cdc.gov/hepatitis/hcv/HepatitisCOverview.htm
Chang, V. T., Hwang, S. S., Kasimis, B., & Thaler, H. T. (2004). Shorter symptom assessment instruments: The Condensed Memorial Symptom Assessment Scale (CMSAS). Cancer Investigation, 22(4), 526-536.
Creswell, J. W. (2015). A concise introduction to mixed methods research. Sage Publications.
Creswell, J. W., Klassen, A. C., Clark, V. L., & Smith, K. C. (2011). Best practices for mixed methods research in the health sciences. https://www.csun.edu/sites/default/files/best_prac_mixed_methods.pdf
Dixon, A., Hibbard, J., & Tusler, M. (2009). How do people with different levels of activation self-manage their chronic conditions? The Patient: Patient-Centered Outcomes Research, 2(4), 257-268. https://doi.org/10.2165/11313790-000000000-00000
Drugs.com. (2020). Zepatier. https://www.drugs.com/zepatier.html
Elo, S., & Kyngas, H. (2008). The qualitative content analysis process. Journal of Advanced Nursing, 62(1), 107-115. https://doi.org/10.1111/j.1365-2648.2007.04569.x
Evon, D. M., Sarkar, S., Amador, J., Lok, A. S., Sterling, R. K., Stewart, P. W., Reeve, B. B., Serper, M., Reau, N., Rajender Reddy, K., Di Bisceglie, A. M., Nelson, D. R., Golin, C. E., Lim, J. K., & Fried, M. W. (2019). Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. Journal of Hepatology, 71(3), 486-497.
Garratt, A. M., Ruta, D. A., Abdalla, M. I., & Russell, I. T. (1994). SF 36 health survey questionnaire: II. Responsiveness to changes in health status in four common clinical conditions. Quality Health Care, 3(4), 186-192.
Gilead Sciences Inc. (2019a). Epclusa. https://www.epclusa.com/
Gilead Sciences Inc. (2019b). Harvoni, Leading the way in Hep C treatment. https://www.harvoni.com/discover-harvoni/about-harvoni?sitelink=&msclkid=dd1d60c9cefc12ce73813e4fb998c765&utm_source=bing&utm_medium=cpc&utm_campaign=Search%20-%20Harvoni%20-%20Decision&utm_term=%2Bharvoni&utm_content=Harvoni%20-%20Broad&gclid=CPKh-d_0yugCFVFMfgodXgIHog&gclsrc=ds
Greene, J., & Hibbard, J. H. (2012). Why does patient activation matter? An examination of the relationships between patient activation and health-related outcomes. Journal of General Internal Medicine, 27(5), 520-526.
Hansen, L., Chang, M., Hiatt, S., Dieckmann, N. F., Mitra, A., Lyons, K., & Lee, C. (2020). Symptom classes in end-stage liver disease: A First Scientific Step. Journal of Pain and Symptom Management, 60(1), 231.
Hibbard, J. H., Stockard, J., Mahoney, E. R., & Tusler, M. (2004). Development of the patient activation measure (PAM): Conceptualizing and measuring activation in patient and consumers. Health Services Research, 39(4), 1005-1026.
Hofmeister, M. G., Rosenthal, E. M., Barker, L. K., Rosenburg, E. S., Barranco, M. A., W. H. E., & Mermin, J. (2018). Estimating prevalence of hepatitis C virus infection in the United States 2013-2016. Hepatology, 69(3), 1020-1031.
Hsieh, H.-F., & Shannon, S. E. (2005). Three approaches to content analysis. Qualitative Health Research, 15, 1277-1288.
Ichikawa, T., Miyaaki, H., Miuma, S., Taura, N., Motoyoshi, Y., Akahoshi, H., Nakamura, S., Nakamura, J., Takahashi, Y., Honda, T., Yajima, H., Uehara, R., Hino, N., Narita, S., Tanaka, H., Sasaki, S., & Nakao, K. (2018). Hepatitis C virus-related symptoms, but not quality of life, were improved by treatment with direct-acting antivirals. Hepatology Research, 48(3), E232-E239. https://doi.org/10.1111/hepr.12974
Insignia Health. (2020). Patient Activation Measure® (PAM®). https://www.insigniahealth.com/
Kutner, J. S., Bryant, L. L., Beaty, B. L., & Fairclough, D. L. (2007). Time course and characteristics of symptom distress and quality of life at the end of life. Journal of Pain and Symptom Management, 34, 227-236.
Marcellin, F., Roux, P., Protopopescu, C., Duracinsky, M., Spire, B., & Carrieri, M. P. (2017). Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: Current knowledge and outstanding issues. Expert Review of Gastroenterology & Hepatology, 11(3), 259-268. https://doi.org/10.1080/17474124.2017.1285227
Marshall, R., Beach, M. C., Saha, S., Mori, T., Loveless, M. O., Hibbard, J. H., Cohn, J. A., Sharp, V. L., & Korthuis, P. T. (2013). Patient activation and improved outcomes in HIV-infected patients. Journal of General Internal Medicine, 28(5), 668-674. https://doi.org/10.1007/s11606-012-2307-y
Miles, B. A., Huberman, A. M., & Saldana, J. (2014). Qualitative data analysis: A methods sourcebook (3rd ed.). Sage Publications.
Pinheiro, J, B. D., DebRoy, S., & Sarkar, D. (2020). nlme: Linear and Nonlinear Mixed Effects Models (Version R package version 3.1-147). https://CRAN.R-project.org/package=nlme
QSR International Pty Ltd. (2017). NVivo qualitative data analysis software. Version 11. http://www.qsrinternational.com/nvivo/nvivo-products/nvivo11-for-windows
R Core Team. (2018). R: A language and environment for statistical computing, Foundation for Statistical Computing. Author.
Saeed, S., Moodie, E. E. M., Strumpf, E., Gill, J., Wong, A., Cooper, C., Walmsley, S., Hull, M., Martel-Laferriere, V., & Klein, M. B. (2018). Real-world impact of direct acting antiviral therapy on health-related quality of life in HIV/Hepatitis C co-infected individuals. Journal of Viral Hepatitis, 25, 1507-1514. https://doi.org/10.1111/jvh.12985
U.S. Department of Health & Human Services. (2014). FDA Approves Viekira Pak To Treat Hepatitis C. https://www.hhs.gov/hepatitis/blog/2014/12/19/fda-approves-viekira-pak-to-treat-hepatitis-c.html
Welzel, T. M., Yang, M., Sajeev, G., Chen, Y. J., Pinsky, B., Bao, Y., Wu, E. Q., & Dieterich, D. (2019). Assessing patient preferences for treatment decisions for new direct-acting antiviral (DAA) therapies for chronic hepatitis C virus infections. Advances in Therapy, 36, 2475-2486. https://doi.org/10.1007/s12325-019-01012-6
Whiteley, D., Whittaker, A., Elliott, L., & Cunningham-Burley, S. (2016). The lived experience of interferon-free treatments for hepatitis C: A thematic analysis. International Journal of Drug Policy, 38, 21-28. https://doi.org/10.1016/j.drugpo.2016.10.013
Younossi, Z. M., Stepanova, M., Henry, L., Nader, F., & Hunt, S. (2016). An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. American Journal of Gastroenterology, 111(6), 808-816.